Company intelligence / Profile preview

ChromSword

Ownership: Private
Development stage: Commercial

Overview

ChromSword develops and commercializes advanced software solutions that automate and optimize high-performance liquid chromatography (HPLC) and ultra-high performance liquid chromatography (UHPLC) method development. Their products are widely used by major pharmaceutical companies to accelerate the creation of robust, validated analytical methods for both small molecules and biopharmaceuticals. The company’s tools leverage artificial intelligence to minimize manual intervention, reduce human error, and significantly shorten the time required for chromatographic method optimization.

Industry: Drug Discovery Services

Partnerships

Thermo Fisher Scientific

Beyond the preview

Go deeper on ChromSword.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ChromSword.

Explore the full profile